Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.
Stephanie Heon
No relevant relationships to disclose
Mizuki Nishino
No relevant relationships to disclose
Sarah B. Goldberg
No relevant relationships to disclose
Jennifer Porter
No relevant relationships to disclose
Lecia V. Sequist
Consultant or Advisory Role - Celgene; Clovis Oncology; Daiichi Sankyo (U); GlaxoSmithKline; Merrimack (U)
David Michael Jackman
Consultant or Advisory Role - Foundation Medicine; Genentech
Bruce E. Johnson
Consultant or Advisory Role - Acceleron Pharma; AstraZeneca; Chugai Pharma; Genentech; Millennium; Pfizer
Stock Ownership - Celgene
Other Remuneration - Genzyme